Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease.

@article{Tariot2011ChronicDS,
  title={Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease.},
  author={Pierre N. Tariot and L. S. Schneider and Jeffrey Cummings and Ronald G. Thomas and Rema Raman and Laura J Jakimovich and Rebekah Loy and Barbara Bartocci and Adam Fleisher and Mohd Mansor Ismail and Anton P. Porsteinsson and Michael Weiner and Clifford R. Jack and Leon Thal and Paul S. Aisen},
  journal={Archives of general psychiatry},
  year={2011},
  volume={68 8},
  pages={
          853-61
        }
}
CONTEXT Agitation and psychosis are common in Alzheimer disease and cause considerable morbidity. We attempted to delay or to prevent agitation and psychosis with the use of divalproex sodium (valproate). OBJECTIVE To determine whether treatment with valproate could delay or prevent emergence of agitation or psychosis. DESIGN, SETTING, AND PATIENTS A multicenter, randomized, double-blind, placebo-controlled trial of flexible-dose valproate in 313 (of 513 screened) individuals with moderate… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 64 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 48 REFERENCES

Longitudinal course of behavioral problems during Alzheimer’s disease: linear ARCH GEN PSYCHIATRY/ VOL 68 (NO

  • HJ McCarty, DL Roth, +4 authors WE. Haley
  • AUG WWW.ARCHGENPSYCHIATRY.COM
  • 2011

Practice guidelines for the treatment of patients with dementia and other dementias , 2 nd ed

  • PV Rabins, D Blacker, +29 authors DA Regier
  • Am J Psychiatry
  • 2007

Valproate - induced changes in brain volume in patients with epilepsy : assessment with HMRS

  • M Garcia, J Huppertz, S Ziyeh, M Buechert, M Schumacher, I Mader
  • Neurology
  • 2006

Similar Papers

Loading similar papers…